Jonathan A. Ledermann

49.6k total citations · 15 hit papers
295 papers, 17.4k citations indexed

About

Jonathan A. Ledermann is a scholar working on Reproductive Medicine, Oncology and Surgery. According to data from OpenAlex, Jonathan A. Ledermann has authored 295 papers receiving a total of 17.4k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Reproductive Medicine, 171 papers in Oncology and 58 papers in Surgery. Recurrent topics in Jonathan A. Ledermann's work include Ovarian cancer diagnosis and treatment (198 papers), PARP inhibition in cancer therapy (114 papers) and BRCA gene mutations in cancer (53 papers). Jonathan A. Ledermann is often cited by papers focused on Ovarian cancer diagnosis and treatment (198 papers), PARP inhibition in cancer therapy (114 papers) and BRCA gene mutations in cancer (53 papers). Jonathan A. Ledermann collaborates with scholars based in United Kingdom, United States and Canada. Jonathan A. Ledermann's co-authors include Gordon C. Jayson, Elise C. Kohn, Henry C Kitchener, Nicoletta Colombo, Antonio González-Martı́n, Michael Friedländer, Gordon Rustin, Philipp Harter, Charlie Gourley and Ignace Vergote and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Jonathan A. Ledermann

286 papers receiving 17.2k citations

Hit Papers

Ovarian cancer 2003 2026 2010 2018 2014 2012 2014 2003 2013 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ovarian cancer
    2014 1.4k citations Gordon C. Jayson, Jonathan A. Ledermann et al. profile →
  2. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    2012 1.3k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  3. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
    2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  4. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
    2003 885 citations Jonathan A. Ledermann, Nicoletta Colombo et al. profile →
  5. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2013 791 citations Jonathan A. Ledermann, Christina Fotopoulou et al. Annals of Oncology profile →
  6. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
    2015 558 citations Nicoletta Colombo, Jonathan A. Ledermann et al. International Journal of Gynecological Cancer profile →
  7. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial
    2013 459 citations Jonathan A. Ledermann et al. profile →
  8. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
    2017 414 citations Jonathan A. Ledermann et al. profile →
  9. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
    2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. profile →
  10. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 304 citations Ana Oaknin, Philipp Harter et al. Annals of Oncology profile →
  11. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
    2020 261 citations Rowan Miller, Alexandra Léary et al. Annals of Oncology profile →
  12. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
    2019 259 citations Nicoletta Colombo, Andreas du Bois et al. International Journal of Gynecological Cancer profile →
  13. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
    2021 160 citations Bradley J. Monk, Nicoletta Colombo et al. profile →
  14. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2023 149 citations Philipp Harter, Alexandra Léary et al. Annals of Oncology profile →
  15. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline
    2022 98 citations Jonathan A. Ledermann et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jonathan A. Ledermann United Kingdom 60 9.2k 8.0k 4.9k 3.1k 2.7k 295 17.4k
Gini F. Fleming United States 60 8.2k 0.9× 5.4k 0.7× 4.1k 0.8× 2.4k 0.8× 3.2k 1.2× 334 16.6k
Carol Aghajanian United States 62 6.1k 0.7× 7.5k 0.9× 3.6k 0.7× 3.2k 1.0× 4.3k 1.6× 425 15.3k
Nicoletta Colombo Italy 66 7.3k 0.8× 10.7k 1.3× 3.3k 0.7× 4.3k 1.4× 6.0k 2.2× 451 18.3k
Ana Oaknin Spain 39 6.8k 0.7× 4.4k 0.5× 3.8k 0.8× 1.8k 0.6× 3.2k 1.2× 320 12.7k
Ursula A. Matulonis United States 77 13.4k 1.5× 8.2k 1.0× 7.9k 1.6× 1.6k 0.5× 2.0k 0.7× 443 23.1k
Robert A. Burger United States 48 4.6k 0.5× 9.1k 1.1× 3.6k 0.7× 4.4k 1.5× 3.7k 1.4× 202 14.8k
Andrew Berchuck United States 73 5.8k 0.6× 6.9k 0.9× 8.1k 1.6× 1.6k 0.5× 4.0k 1.5× 358 19.9k
Karen H. Lu United States 72 6.8k 0.7× 8.3k 1.0× 7.4k 1.5× 2.1k 0.7× 5.3k 1.9× 427 21.6k
Gunnar B. Kristensen Norway 59 4.3k 0.5× 7.6k 0.9× 3.6k 0.7× 3.8k 1.2× 4.4k 1.6× 266 14.7k
Gordon Rustin United Kingdom 67 5.3k 0.6× 5.1k 0.6× 4.0k 0.8× 3.4k 1.1× 1.3k 0.5× 245 16.0k

Countries citing papers authored by Jonathan A. Ledermann

Since Specialization
Citations

This map shows the geographic impact of Jonathan A. Ledermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan A. Ledermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan A. Ledermann more than expected).

Fields of papers citing papers by Jonathan A. Ledermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan A. Ledermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan A. Ledermann. The network helps show where Jonathan A. Ledermann may publish in the future.

Co-authorship network of co-authors of Jonathan A. Ledermann

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan A. Ledermann. A scholar is included among the top collaborators of Jonathan A. Ledermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan A. Ledermann. Jonathan A. Ledermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roncolato, Felicia, Madeleine King, Rachel O’Connell, et al.. (2024). Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. Gynecologic Oncology. 185. 128–137. 3 indexed citations
2.
El-Shakankery, Karim, Kieran Palmer, Uma Mukherjee, et al.. (2024). Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London. Cancers. 16(21). 3590–3590.
3.
Bonaca, Marc P., Javid J. Moslehi, Jonathan A. Ledermann, et al.. (2023). Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. The Oncologist. 28(10). e977–e980. 1 indexed citations
4.
Coleman, Robert L., Amit M. Oza, Domenica Lorusso, et al.. (2022). 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. International Journal of Gynecological Cancer. 32. A226–A226. 16 indexed citations
5.
Kacperczyk‐Bartnik, Joanna, et al.. (2022). Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022. International Journal of Gynecological Cancer. 33(2). 175–182. 4 indexed citations
6.
Sundar, Sudha, Rebecca Bowen, Christina Fotopoulou, et al.. (2022). British Gynaecological Cancer Society Recommendations for Women With Gynecological Cancer Who Received Non-standard Care During the COVID-19 Pandemic. Obstetrical & Gynecological Survey. 77(3). 156–157. 1 indexed citations
7.
Ángeles, Martina Aida, Félix Boria, Nicolò Bizzarri, et al.. (2022). Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative. International Journal of Gynecological Cancer. 33(1). 12–18. 2 indexed citations
8.
Friedländer, Michael, Sarah J. Lord, Rebecca Asher, et al.. (2021). Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer. 154. 190–200. 9 indexed citations
9.
Willis, Sophie E., C Winkler, Martine P. Roudier, et al.. (2021). Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British Journal of Cancer. 125(12). 1666–1676. 31 indexed citations
10.
Taylor, Alexandra, Sudha Sundar, Rebecca Bowen, et al.. (2021). British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic. International Journal of Gynecological Cancer. 32(1). 9–14. 2 indexed citations
11.
Dean, Andrew, Amit M. Oza, Domenica Lorusso, et al.. (2020). 821P Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase III ARIEL3 study. Annals of Oncology. 31. S620–S621. 1 indexed citations
12.
Coosemans, An, Thaïs Baert, Louis Boon, et al.. (2019). Combining conventional therapy with immunotherapy: A risky business?. European Journal of Cancer. 113. 41–44. 24 indexed citations
13.
Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. UCL Discovery (University College London). 1 indexed citations
14.
Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2014). Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer. Obstetrical & Gynecological Survey. 69(10). 594–596. 14 indexed citations
15.
Collinson, Fiona, Rachel A. Craven, David A. Cairns, et al.. (2013). Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection. Clinical Cancer Research. 19(18). 5227–5239. 58 indexed citations
16.
Ledermann, Jonathan A., Allan Hackshaw, Gordon C. Jayson, et al.. (2011). Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer. Journal of Clinical Oncology. 29(28). 3798–3804. 164 indexed citations
17.
Kingsbury, Sarah R., Slavica Tudzarova, Hye-Kyung Hong, et al.. (2009). Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma. Clinical Cancer Research. 15(7). 2417–2425. 59 indexed citations
18.
Newton, Claire, et al.. (2007). Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. British Journal of Cancer. 97(7). 927–933. 63 indexed citations
19.
Pedrazzoli, Paolo, Jonathan A. Ledermann, Jean‐Pierre Lotz, et al.. (2006). High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Annals of Oncology. 17(10). 1479–1488. 44 indexed citations
20.
Ledermann, Jonathan A. & Robert L. Souhami. (1993). Biology of lung cancer. Current Opinion in Oncology. 5(2). 294–301. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gini F. Fleming Breakdown of academic impact, for papers by Carol Aghajanian Breakdown of academic impact, for papers by Nicoletta Colombo Breakdown of academic impact, for papers by Ana Oaknin Breakdown of academic impact, for papers by Ursula A. Matulonis Breakdown of academic impact, for papers by Robert A. Burger Breakdown of academic impact, for papers by Andrew Berchuck Breakdown of academic impact, for papers by Karen H. Lu Breakdown of academic impact, for papers by Gunnar B. Kristensen Breakdown of academic impact, for papers by Gordon Rustin
Rankless by CCL
2026